Free tool
FAERS Monitor: Ngenla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761184 or its brand name (Ngenla, Somatrogon-Ghla). Reports on generic versions are filed under their own applications.
Reports
1,247
Serious
206
17% of reports
Hospitalization
49
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain805
- wrong technique in device usage process49
- injection site erythema48
- incorrect dose administered by device47
- drug dose omission by device43
- injection site swelling40
- headache38
- device mechanical issue36
- needle issue36
- device delivery system issue33
- patient-device incompatibility33
- off label use32
- device leakage28
- incorrect dose administered27
- injection site mass27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 277 |
| 2024 | 530 |
| 2025 | 344 |
| 2026 | 95 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| patient-device incompatibilitySignal | 33 | 857.1 | 606.8 | 26,048 |
| device mechanical issueSignal | 36 | 44.4 | 32.2 | 1,481 |
| injection site painSignal | 805 | 44.4 | 42.6 | 34,503 |
| incorrect dose administered by deviceSignal | 47 | 30.3 | 22.9 | 1,302 |
| needle issueSignal | 36 | 20.9 | 15.1 | 662 |
| device delivery system issueSignal | 33 | 20.4 | 14.5 | 588 |
| wrong technique in device usage processSignal | 49 | 17.7 | 13.5 | 757 |
| injection site massSignal | 27 | 12.3 | 8.5 | 270 |
| device leakageSignal | 28 | 10.9 | 7.6 | 242 |
| drug dose omission by deviceSignal | 43 | 9.3 | 6.9 | 310 |
| injection site swellingSignal | 40 | 8.8 | 6.5 | 270 |
| injection site erythemaSignal | 48 | 6.5 | 4.9 | 220 |
| incorrect dose administered | 27 | 2.0 | 1.4 | 13 |
| headache | 38 | 1.0 | 0.7 | 0 |
| off label use | 32 | 0.6 | 0.4 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.